DaVita's stock is in a sustained uptrend, with a 1-year price change of +65.27%, significantly outperforming the S&P 500's 18.35% gain. The current price of $236.97 sits at 98.9% of its 52-week range (high $239.64, low $101.00), indicating strong momentum and near-term overextension, but also reflecting robust investor confidence. The stock has rallied from its 52-week low of $101.00, representing a gain of over 134% from that level, suggesting a powerful recovery trend. Short-term momentum is accelerating, with 1-month and 3-month price changes of +12.53% and +60.21%, respectively, both outpacing the S&P 500's 0.31% and 4.67% gains. The 1-month relative strength of +12.22% confirms strong near-term buying pressure, while the 3-month relative strength of +55.54% indicates that the stock is in a powerful uptrend that has recently intensified. The 52-week high of $239.64 acts as immediate resistance, while the 52-week low of $101.00 provides a distant support level. A breakout above $239.64 would signal a continuation of the uptrend, potentially targeting new highs. The stock's beta of 0.882 indicates it is less volatile than the market, which is unusual given its recent sharp gains, but suggests that the move is driven by company-specific factors rather than broad market risk.

DaVita's revenue trajectory is steadily growing, with Q1 2026 revenue of $3.416 billion, up 5.96% year-over-year from $3.224 billion in Q1 2025. The multi-quarter trend shows consistent sequential growth, with revenue increasing from $3.180 billion in Q2 2024 to $3.620 billion in Q4 2025, indicating a healthy expansion. The U.S. dialysis and related lab services segment generated $10.123 billion in the latest fiscal year, representing the core driver of growth. This steady revenue growth supports the investment case, as it reflects stable patient volumes and pricing power in a regulated environment. The company is profitable, with Q1 2026 net income of $197.53 million and a gross margin of 31.42%. Gross margins have been relatively stable, ranging from 28.28% in Q4 2025 to 33.08% in Q2 2025, indicating consistent cost management. Operating margin improved to 14.11% in Q1 2026 from 13.62% in Q1 2025, reflecting operational efficiency gains. Net income has grown from $162.92 million in Q1 2025 to $197.53 million in Q1 2026, a 21.2% increase, demonstrating improving profitability. DaVita's balance sheet shows a debt-to-equity ratio of -23.12, which is negative due to negative shareholders' equity, a common characteristic in highly leveraged companies. However, the company generated strong free cash flow of $218.81 million in Q1 2026 and $1.493 billion on a trailing twelve-month basis, providing ample liquidity for debt service and reinvestment. The current ratio of 1.29 indicates adequate short-term liquidity, while the negative ROE of -114.7% is a result of negative equity, but the company's operating performance remains solid.